Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development of a breast cancer risk assessment model for ATM mutation carriers incorporating tyrer-cuzick and a polygenic risk score (PRS)
    Meeting Abstract

    Gallagher, S.; Hughes, E.; Rosenthal, E.; Kurian, A. W.; Domchek, S.; Garber, J.; Probst, B.; Morris, B.; Tshiaba, P.; Roa, B.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
    Meeting Abstract

    Ellis, M. J.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • The optimal living and survivorship program: Piloting a novel cancer survivorship care model
    Meeting Abstract

    Corcoran, S.; Russell, J.; Clayton, J.; Smith, A.; Keenan, K.; Robson, M.; Iyengar, N.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Fertility preservation in young women with breast cancer: Impact on treatment and outcomes
    Meeting Abstract

    Crown, A.; Muhsen, S.; Sevilimedu, V.; Kelvin, J.; Goldfarb, S. B.; Gemignani, M. L.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Pregnancy-associated breast cancer: Does timing of presentation affect outcome?
    Meeting Abstract

    Crown, A.; McCartan, D.; Curry, M.; Feldman, M.; Patil, S.; Kamer, S.; Goldfarb, S. B.; Gemignani, M.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer
    Meeting Abstract

    DieĢras, V.; Weaver, R.; Tolaney, S. M.; Bardia, A.; Punie, K.; Brufsky, A.; Rugo, H. S.; Kalinsky, K.; Traina, T.; Klein, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Secondary outcomes in a randomized controlled trial of acupuncture versus sham acupuncture and usual care in solid tumor survivors with chemotherapy-induced peripheral neuropathy
    Meeting Abstract

    Bao, T.; Baser, R.; Lin, C.; Li, Q.; Piulson, L.; Zhi, I.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
    Meeting Abstract

    Beckwith, H. C.; Medgyesy, D. C.; Abraham, J.; Nanda, R.; Tkaczuk, K. H. R.; Krop, I. E.; Pusztai, L.; Modi, S.; Mita, M. M.; Specht, J. M.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save